Abstract:IMPORTANCE Evidence on the timing of fetal growth alterations associated with gestational diabetes or on the association of the maternal glycemic trajectory with fetal growth during pregnancy remains lacking. OBJECTIVE To examine the associations between maternal glucose levels and offspring intrauterine growth. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from 4574 eligible pregnant women and their offspring in the Shanghai Maternal-Child Pairs Cohort collected from April 10, 2016, to April 30, 2018. Group-based trajectory modeling was used to classify fasting plasma glucose levels during pregnancy into 3 glycemic trajectories (trajectory 1, consistently normal glucose levels in all 3 trimesters; trajectory 2, hyperglycemia only in late pregnancy; and trajectory 3, hyperglycemia in all 3 trimesters [ie, consistently high glucose levels]). Statistical analysis was performed from April 25, 2020, to October 1, 2021. EXPOSURES Gestational diabetes, which was defined using the results of an oral glucose tolerance test. MAIN OUTCOMES AND MEASURES Longitudinal fetal biometrics during gestational weeks 11 to 40 and birth outcomes were obtained from medical records. Pregnancy was partitioned into 3 periods (<24, 24-34, and >34 weeks' gestational age). The differences in offspring growth (log-transformed) and maternal glucose levels were compared using generalized linear mixed models. RESULTS A total of 4121 pregnant women had oral glucose tolerance test results (mean [SD] age, 28.8 [4.1] years), 3746 of whom had glycemic trajectory data (mean [SD] age, 28.6 [4.1] years); 983 women (23.8%) had gestational diabetes. Throughout the pregnancy period and compared with the women without gestational diabetes or with women in the trajectory 1 group, the fetal biometrics for the women with gestational diabetes or for those in the trajectory 3 group were significantly higher (except for bi parietal diameter), with an estimated increase in fetal weight in the group with gestational diabetes (beta = 1.82; 95% CI, 1.03-2.61) and in the trajectory 3 group (beta = 1.50; 95% CI, 0.54-2.47; P = .002). Fetal biometric alterations among women with gestational diabetes appeared before 24 weeks' gestational age, with neonatal birth weight significantly higher than in the group without gestational diabetes at 40.4 g (95% CI. 9.8-71.1 g) along with an increased risk of large size for gestational age (odds ratio, 1.36; 95% CI, 1.05-1.75) and macrosomia (odds ratio, 1.47; 95% CI, 1.12-1.94). However, pregnant women in the trajectory 2 group manifested significantly reduced fetal biometrics, and abdominal circumference was significantly augmented after 34 weeks' gestational age (increase, beta = 1.92; 95% CI. 0.87-2.99). CONCLUSIONS AND RELEVANCE In this cohort study, pregnant women who received a diagnosis of gestational diabetes in midpregnancy or had hyperglycemia during all 3 trimesters showed an association with altered fetal growth patterns, including increased estimated fetal weight that appeared before 24 weeks' gestational age, increased birth weight, and the risk for large size for gestational age and macrosomia.

Analysis of self‐monitoring of blood glucose metrics in gestational diabetes mellitus and their association with infants born large for gestational age: A historical observational cohort study of 879 pregnancies

The Association of Gestational Diabetes Mellitus with Fetal Birth Weight.

Relationship of Abnormal Mid-Term Oral Glucose Tolerance Test and Maternal Weight Gain with Adverse Pregnancy Outcomes in Women with Gestational Diabetes Mellitus

The Influence of HbA1c and Gestational Weight Gain on Pregnancy Outcomes in Pregnant Women with Gestational Diabetes Mellitus

1039-P: Association of GDM Risk Factors with Glucose at Diagnosis and Treatment in Sweden

Effect of Maternal Lipid Profile, C-peptide, Insulin, and HBA1c Levels During Late Pregnancy on Large-for-gestational Age Newborns

[Association between abnormal oral glucose tolerance test patterns in the second trimester and large for gestational age newborns]

Late-Pregnancy Dysglycemia after Negative Testing for Gestational Diabetes and Risk of the Large-for-Gestational-Age Newborns: A Nest Case-Control Study Based on the Xi'an Longitudinal Mother-Child Cohort Study

Continuous Glucose Monitoring-Derived Differences in Pregnancies With and Without Adverse Perinatal Outcomes

Large for Gestational Age and Adverse Outcomes: Stratified By Diabetes Status

The impact of glycosylated hemoglobin and 75-g oral glucose tolerance test glucose levels on birthweight percentile

1174-P: Characterization of Glucose Levels in Pregnancy Measured by Blood Glucose Testing or CGM Monitoring after a 50-g Screening or a 75-g or 100-g OGTT

Fasting blood glucose as a screening measure for late-onset gestational diabetes in the third trimester

Longitudinal Associations Between Maternal Glucose Levels and Ultrasonographic Fetal Biometrics in a Shanghai Cohort

Functional analysis of daily glycemic profiles and excessive fetal growth in pregnant patients with well-controlled type 1 diabetes: Retrospective cohort

Fasting Glucose Level on the Oral Glucose Tolerance Test Is Associated with the Need for Pharmacotherapy in Gestational Diabetes Mellitus

First trimester maternal serum PAPP-A and free β-hCG levels and risk of SGA or LGA in women with and without GDM

Birth weight and large for gestational age trends in offspring of pregnant women with gestational diabetes mellitus in southern China, 2012-2021

Gestational Diabetes Mellitus, Pre-Pregnancy Body Mass Index and Gestational Weight Gain Predicts Fetal Growth and Neonatal Outcomes.

Post‐load glucose is a stronger predictor of adverse pregnancy outcomes than first‐trimester HbA1c in women without gestational diabetes

[Analysis of the Effects of Gestational Diabetes Mellitus Based on Abnormal Blood Glucose on Pregnancy Outcomes].